Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.
Also called NCT02638805
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 136 participants
- Sponsor
- Registry
-
NCT02638805
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02638805. Randomized; no masking; primary purpose treatment. Start 2015-12 (registry gives no type); primary completion 2017-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- ITCA 650 Osmotic Mini Pump 20/60 mcg/day
- Intervention (Drug)
- ITCA 650 Osmotic Mini Pump 60 mcg/day
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Liraglutide
- Lead sponsor
- Intarcia Therapeutics
Record details
- Record id
cardio:ct-nct02638805- Content hash
12f0d8d8b0cb518c868e9b48f144716694917b3d9c78d099a530038489e3675c